| Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans. | |
| | |
MedLine Citation:
|
PMID: 20145261 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This study compared the gastrointestinal (GI) absorption characteristics and absolute bioavailability of fenofibric acid and fenofibrate (which is converted to fenofibric acid in vivo) in healthy volunteers. Treatments were delivered to the proximal small bowel, distal small bowel, and colon using a site-specific delivery system (Enterion capsule) and to the stomach by oral administration of equimolar doses. Serial blood samples were collected for 120 hours postdose and assayed for plasma fenofibric acid concentrations. The absolute bioavailability of each treatment was determined relative to 50 mg of fenofibric acid administered intravenously. Plasma exposure to fenofibric acid following fenofibric acid administration was approximately 1.5 times higher than that following fenofibrate administration for delivery to the proximal and distal small bowel and following oral administration, and it was approximately 5 times higher following colon delivery. The absolute bioavailability in the stomach, proximal small bowel, distal small bowel, and colon was approximately 81%, 88%, 84%, and 78%, respectively, for fenofibric acid and 69%, 73%, 66%, and 22%, respectively, for fenofibrate (P < .0001 and P = .033 for fenofibric acid vs fenofibrate in the colon and distal small bowel, respectively). In conclusion, fenofibric acid is well absorbed throughout the GI tract and has greater bioavailability than fenofibrate in all GI regions. |
| | |
Authors:
|
Tong Zhu; Jean-Claude Ansquer; Maureen T Kelly; Darryl J Sleep; Rajendra S Pradhan |
Publication Detail:
|
Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-02-09 |
Journal Detail:
|
Title: Journal of clinical pharmacology Volume: 50 ISSN: 1552-4604 ISO Abbreviation: J Clin Pharmacol Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-20 Completed Date: 2010-11-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0366372 Medline TA: J Clin Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 914-21 Citation Subset: IM |
Affiliation:
|
100 Abbott Park Road, Dept R4PK, Bldg AP13A-3, Abbott Park, IL 60064-6104, USA. tong.zhu@abbott.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adolescent Adult Antilipemic Agents / administration & dosage, pharmacokinetics* Area Under Curve Biological Availability Drug Delivery Systems Half-Life Humans Injections, Intravenous Intestinal Absorption Male Metabolic Clearance Rate Middle Aged Procetofen / administration & dosage, analogs & derivatives*, pharmacokinetics Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 26129-32-8/fenofibric acid; 49562-28-9/Procetofen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding ...
Next Document: Pharmacokinetics, Pharmacodynamics, and Metabolism of Triethylenetetramine in Healthy Human Particip...